Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease?

  • M. Taraborelli | mara.taraborelli@libero.it Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia; Rheumatology Chair, University of Pavia., Italy.
  • F. Inverardi Rheumatology Chiar, University of Pavia., Italy.
  • M. Fredi Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia; Rheumatology Chair, University of Pavia., Italy.
  • A. Ceribelli Department of Oral Biology, University of Florida, Gainesville, Florida, United States.
  • I. Cavazzana Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia;, Italy.
  • A. Tincani Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia;, Italy.
  • F. Franceschini Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia;, Italy.

Abstract

A small number of systemic lupus erythematosus (SLE) patients develop an erosive disease. Some studies have suggested an association between anti-cyclic citrullinated (anti-CCP) antibodies and this pattern of arthritis, but their exact significance in SLE patients remains unclear. The aim of this study was to evaluate the prevalence of anti-CCP antibodies in SLE patients with different subsets of articular disease. Among 521 SLE patients followed in this center from 1976 to 2011, those with articular involvement (n=298) were selected to take part in the study. We searched for anti-CCP2 IgG antibodies in 198 patients using a commercial enzyme linked immunosorbent assay (Immunoscan RA, Eurodiagnostica). In 174 patients the results for rheumatoid factor (RF) by nephelometry were retrospectively collected. C reactive protein (CRP) was obtained from clinical records. Patients were classified into 3 groups: erosive, non-erosive deforming, non-erosive non-deforming arthritis. Results of the different tests were compared among the groups. P<0.05 was considered statistically significant. Anti-CCP antibodies were significantly associated with erosive disease. We also found that RF positivity and increased CRP were more frequent in erosive arthritis and erosive or non-deforming arthritis, respectively, than in non-erosive non-deforming arthritis. This study supports the evidence that anti-CCP antibodies could be a useful marker of erosive disease in SLE patients. Increase in RF and CRP could be an additional means of identifying lupus patients with arthritis at risk of a worse prognosis.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Author Biographies

M. Taraborelli, Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia; Rheumatology Chair, University of Pavia.
no
F. Inverardi, Rheumatology Chiar, University of Pavia.
no
M. Fredi, Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia; Rheumatology Chair, University of Pavia.
no
A. Ceribelli, Department of Oral Biology, University of Florida, Gainesville, Florida
no
I. Cavazzana, Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia;
no
A. Tincani, Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia;
no
F. Franceschini, Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia;
no
Published
2012-12-11
Info
Issue
Section
Articles
Keywords:
Systemic Lupus Erythematosus, anti-cyclic citrullinated peptide antibodies, arthtritis
Statistics
  • Abstract views: 1102

  • PDF: 875
How to Cite
Taraborelli, M., Inverardi, F., Fredi, M., Ceribelli, A., Cavazzana, I., Tincani, A., & Franceschini, F. (2012). Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease?. Reumatismo, 64(5), 321-325. https://doi.org/10.4081/reumatismo.2012.321